Table 1.
Patient and tumor characteristics for IG-IMRT (n = 49) and RP followed by IMRT (n = 49)
|
Characteristics |
Total |
RP + IMRT |
IG-IMRT |
p-value |
|---|---|---|---|---|
| (n = 98) | (n = 49) | (n = 49) | ||
| Median age – years [range] |
66.8 [51.7-82.7] |
64.8 [51.7-82.7] |
70.2 [53.3-82.4] |
< 0.001 £ |
| Median follow-up – months [range] |
56.6 [18.22-115.1] |
51.5 [18.2-115.1] |
62.2 [25.5-106.0] |
|
| Clinical T stage |
1.0 $ |
|||
| T1c – n (%) |
60 (61.2%) |
30 (61.2%) |
30 (61.2%) |
|
| T2 – n (%) |
4 (4.1%) |
2 (4.1%) |
2 (4.1%) |
|
| T2a – n (%) |
14 (14.3%) |
7 (14.3%) |
7 (14.3%) |
|
| T2b – n (%) |
20 (20.4%) |
10 (20.4%) |
10 (20.4%) |
|
| Gleason score on biopsy |
1.0 μ |
|||
| ≤ 6 – n (%) |
58 (59.2%) |
29 (59.2%) |
29 (59.2%) |
|
| 7 – n (%) |
40 (40.8%) |
20 (40.8%) |
20 (40.8%) |
|
| Pretherapeutic PSA |
0.632 # |
|||
| Median value – ng/mL [range] |
8.7 [1.7 - 32] |
8.7 [2.7 - 29] |
8.7 [1.7 - 32] |
|
| Risk group |
1.0 $ |
|||
| Low |
30 (30.6%) |
15 (30.6%) |
15 (30.6%) |
|
| Intermediate |
62 (63.3%) |
31 (63.3%) |
31 (63.3%) |
|
| High |
6 (6.1%) |
3 (6.1%) |
3 (6.1%) |
|
| Concomitant hormones with radiation |
1.0 μ |
|||
| n (%) |
20 (20.4%) |
10 (20.4%) |
10 (20.4%) |
|
| Adjuvant hormones with radiation |
0.564 μ |
|||
| n (%) |
14 (14.3%) |
6 (12.2%) |
8 (16.3%) |
|
| Mean dose of radiotherapy | ||||
| Prostatic fossa – median value (Gy) [range] |
70.0 [31.4 – 79.8] |
66.0 [31.4 – 70.3] |
77.4 [73.0 – 79.8] |
< 0.001 # |
| Rectum – median value (Gy) [range] |
38.1 [4.8 – 61.1] |
36.0 [4.8 – 57.1] |
39.3 [26.5 – 61.1] |
0.061 # |
| Bladder – median value (Gy) [range] | 32.7 [15.5 – 67.3] | 43.6 [16.8 – 63.7] | 31.3 [15.5 – 67.3] | < 0.001 £ |
* Union for International Cancer Control classification 2002 (6th edition); £ Student’s test; $ Fisher’s exact test; # Kruskall Wallis test; μ: Chi2.
IG-IMRT: Image-guided intensity modulated radiotherapy; RP: radical prostatectomy, PSA: Prostate Specific Antigen.